Login
$SBRA
$20.35 -$0.09 (0.44%) Live

$SBRA 8-K SEC Filings

Filed On Filing
02 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The table below sets forth our 2026 guidance (per diluted common share):

03 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The table below sets forth our 2026 guidance (per diluted common share):

21 Jul 2026 8-K: Regulation FD Disclosure

TUSTIN, CA, July 21, 2026 — Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq: SBRA) today announced a business update detailed below.

17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

(a) The annual meeting of stockholders of the Company (the “Annual Meeting”) was held on June 17, 2026.

28 May 2026 8-K: Regulation FD Disclosure

Strategic. Disciplined. Opportunistic. Investor Presentation | May 28, 2026

29 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

(1) Other normalizing items for FFO and AFFO primarily include triple-net operating expenses, net of recoveries.

12 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The table below sets forth our 2026 guidance (per diluted common share):

05 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into this 1st day of January, 2026 (the “Effective Date”), by and between Darrin Smith (“Executive”) and Sabra Health Care REIT, Inc., a Maryland corporation (“Sabra” or the “Company”).

05 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The table below sets forth our 2025 guidance (per diluted common share):

05 Aug 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

We have served as Maryland counsel to Sabra Health Care REIT, Inc., a Maryland corporation (the “Company”), in connection with certain matters of Maryland law relating to the sale and issuance of shares (the “Shares”) of common stock, $0...

04 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The table below sets forth our 2025 guidance (per diluted common share):

31 Jul 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

4378364.5 CREDIT AGREEMENT Dated as of July 30, 2025 among SABRA HEALTH CARE LIMITED PARTNERSHIP and SABRA CANADIAN HOLDINGS, LLC, as Borrowers, SABRA HEALTH CARE REIT, INC., and CERTAIN SUBSIDIARIES OF SABRA HEALTH CARE REIT, INC. FROM ...

30 Jun 2025 8-K: Other Events

On June 30, 2025, Sabra Health Care REIT, Inc. (the “Company”) announced that its subsidiary, Sabra Health Care Limited Partnership (the “Limited Partnership”), will redeem all $500 million aggregate principal amount of its outstanding 5...

12 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

(a) The annual meeting of stockholders of the Company (the “Annual Meeting”) was held on June 12, 2025.

05 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

(1) Other normalizing items for FFO and AFFO primarily include triple-net operating expenses, net of recoveries.

24 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This Consulting Agreement (“Agreement”), dated as of March 20, 2025, is made and entered into by and between Talya Nevo-Hacohen (“Consultant”) and Sabra Health Care REIT, Inc. (“Company”).

19 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The table below sets forth our 2025 guidance (per diluted common share):

12 Nov 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

31 Oct 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The table below sets forth our 2024 guidance (per diluted common share):

07 Aug 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The table below sets forth our 2024 guidance (per diluted common share):

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support